Acute myeloid leukemia (AML) with complex karyotype is characterized by high genomic complexity, including frequent TP53 mutations and chromothripsis. Genomic rearrangements can reposition active enhancers near proto-oncogenes, leading to their aberrant expression; however, a comprehensive understanding of these events in AML is still incomplete. To facilitate the discovery of such “enhancer hijacking” events, we developed Pyjacker, a computational tool, and applied it to 39 AML samples with complex karyotype. Pyjacker identified several enhancer hijacking events in AML patient samples, including aberrant expression of MNX1, which can result from del(7)(q22q36) and is associated with hijacking of a CDK6 enhancer. MNX1 activation occurred in 1.4% of patients with AML and showed significant co-occurrence with BCOR mutations. Through a xenograft mouse model, we demonstrated that MNX1 is required for leukemia cell fitness. Pyjacker is an easy-to-use, accurate, and broadly applicable tool for identifying consequences of genomic events driving tumorigenesis, especially when germline genomic data are missing. Significance: This study examines the consequences of structural alterations in AML and demonstrates that proto-oncogene activation by enhancer hijacking is an understudied pathomechanism. MNX1 overexpression demonstrates that deletions on chromosome 7q can not only lead to haploinsufficiency but also to activation of oncogenes by enhancer hijacking.
Supplementary Figure 1. Summary of the somatic alterations in the 39 ckAML samples. Supplementary Figure 2. Proportion of samples expressing the top pyjacker hits, for several AML cohorts profiled with RNA-seq. Supplementary Figure 3. Example rearrangements leading to gene activation and TP53 inactivation. Supplementary Figure 4. Rearrangements leading to MECOM monoallelic expression in sample 15KM20146. Supplementary Figure 5. Validation of the translocation t(1;3)(p36;q21) in sample 16KM11270 and of the breakpoints for the CDK6 enhancer duplication next to MNX1 in sample 15PB8708 by genomic PCR. Supplementary Figure 6. Deletion between the TCR beta locus and MNX1 leading to MNX1 expression. Supplementary Figure 7. Alternative rearrangements leading to MNX1 expression. Supplementary Figure 8. Differential gene expression analysis of MNX1 status in adult and pediatric AML. Supplementary Figure 9. Gene expressions of 25 selected cancer and hematological development associated genes differentially expressed under MNX1 activation. Supplementary Figure 10. Copy number alterations on chromosome 7 for samples profiled with scRNA-seq. Supplementary Figure 11. Reciprocal 4C. Supplementary Figure 12: Knockdown of MNX1 reduces tumor load of AML PDX cells in vivo.
Putative enhancers in the CDK6 region interact with MNX1 in del(7q) AML. A, Chromatin interaction detected with 4C in the region around CDK6 using MNX1 as viewpoint, for three different del(7)(q22q36) samples and one control sample (GDM-1 cell line) without del(7q). B, The 200 kb search region based on the enhancer duplication (sample 15PB8708) and the sample with the leftmost deletion (MLL215704), with tracks for enhancer marks: ATAC-seq in del(7q) samples MTM9 and 2KFQ, ATAC-seq and ACT-seq against H3K27ac and H3K4me1 in the PDX sample AML-661 derived from a del(7q) patient, and ChIP-seq against P300 and H3K27ac in the MOLM-1 cell line. The putative enhancers are highlighted in orange. C, Copy number (CN) profile and SVs on chromosome 7 in the engineered cell line validating the insertion of the 1 kb region. D, Circos plot for the same cell line showing the absence of other rearrangements. Copy number losses are indicated in blue, and gains in red. SVs are shown as arcs at the center, with interchromosomal breakpoints in green, duplications in red, deletions in blue, and inversion in purple. E,MNX1 expression in TPM for the parental ChiPSC22 HSPCs (n = 5, from independent differentiation experiments) compared with the engineered cell with the enhancer insertion (enh ins; n = 8, from independent differentiation experiments for two different cell lines). **, P < 0.01 using a two-sided t test. chr, chromosome.
MNX1 is expressed in 1.4% of all AML cases, often with del(7)(q22q36). A, qRT-PCR screen for MNX1 expression in three AML cohorts (Rotterdam, Ulm, and Jena). B, Fifteen MNX1-expressing samples with del(7)(q22q36) profiled with WGS, with a zoom-in around the breakpoints (hg19 reference). The blue rectangles indicate the genomic regions that are retained, and dashed lines represent breaks. C, Percentage of samples with mutations in frequently mutated genes for MNX1+ samples with breakpoints near MNX1, MNX1+ samples without breakpoints, and TCGA-LAML samples. D, scRNA-seq analysis for MNX1+ and control del(7q) AML samples. Left, UMAP showing cell type labels of 53,479 cells integrated across eight patients. Right, UMAP highlighting MNX1 expression (top) and the presence of a del(7q) (bottom) as predicted for patients with del(7q) (n = 4) and patients with del(7q) and MNX1 activation (n = 4). chr, chromosome; UMAP, Uniform Manifold Approximation and Projection.
Detection of enhancer hijacking in 39 ckAML samples. A, Schematic representation of the main sources of information used by Pyjacker: breakpoints, overexpression, monoallelic expression, and enhancers. B, Scatter plot of genes identified by Pyjacker in 39 ckAML samples as being potentially activated by genomic rearrangements in one or more samples, in which the x-axis shows the genomic location of the genes, and the y-axis shows the FDR. Gene names for the enhancer hijacking candidates are written in bold, and if a fusion transcript is detected, the fusion partner is named. chr, chromosome.
ST1 Methods for enhancer hijacking detection ST2 Ranked and scored hematopoietic enhancers (based on ChIP-seq data for H3K27ac and P300 from K562, MOLM1 and Kasumi1) ST3 Pyjacker results for the 10 AML cell lines ST4 Pyjacker results for the 120 medulloblastoma samples ST5 Cis-x results for the 120 medulloblastoma samples ST6 Summary information for the 39 ckAML patient samples ST7 SNVs detected in WGS data for the 39 ckAML samples ST8 SVs detected in WGS data for the 39 ckAML samples ST9 CNAs detected in WGS data for the 39 ckAML samples ST10 Fusion transcripts detected in RNAseq data for the 39 ckAML samples ST11 Pyjacker results for the 39 ckAML samples ST12 Primers for qRT-PCR and validation of breakpoints (hg19) ST13 Summary of the MNX1 expression screens ST14 Summary of the MNX1-expressing samples profiled with WGS ST15 Mutations detected in the MNX1-expressing samples profiled with WGS ST16 Results of the differential expression analysis (adult and pediatric AML) ST17 TADs derived from HiC data of HSPCs ST18 Samples IDs from the TARGET-AML cohort used for the RNA-seq analysis ST19 Clinical characteristics of the patient samples from which were derived the PDX ST20 Primers and conditions used for 4C ST21 Antibodies used